NasdaqGM:MIRMBiotechs
Mirum Pharmaceuticals (MIRM) Stock Looks Fully Valued On Current Sales Expectations
Mirum Pharmaceuticals has delivered a very large 5 year return for shareholders, yet the stock now screens as overvalued on market multiples and the broader valuation checks point to a mixed picture rather than a clear bargain.
Over the past 5 years, Mirum Pharmaceuticals has returned roughly 7x for investors, which puts extra focus on whether the current share price already reflects much of the good news.
Expectations for continued progress from Mirum Pharmaceuticals' drug portfolio can...